Waqas Azeem

Researcher

Academic article

Show author(s) (2023). GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2. Frontiers in Immunology. 15 pages.
Show author(s) (2023). A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. Cancer Immunology and Immunotherapy.

Show author(s) (2022). Proteasome‐mediated regulation of GATA2 expression and androgen receptor transcription in benign prostate epithelial cells. Biomedicines. 14 pages.
Show author(s) (2022). Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain. Frontiers in Pharmacology. 15 pages.

Show author(s) (2021). Evaluation of β-catenin inhibition of axitinib and nitazoxanide in human monocyte-derived dendritic cells. Biomedicines. 1-18.

Show author(s) (2020). Dual pro- and anti-inflammatory features of monocyte-derived dendritic cells. Frontiers in Immunology. 1-15.

Show author(s) (2018). Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain. Pharmacology Research & Perspectives. 1-15.

Show author(s) (2017). An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells. PLOS ONE. 1-20.

Show author(s) (2016). Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. BMC Cancer. 15 pages.

Show author(s) (2014). Activation of peroxisome proliferator-activated receptor gamma leads to upregulation of ESE-3 expression in human monocyte-derived dendritic cells. Scandinavian Journal of Immunology. 20-26.

Academic lecture

Show author(s) (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC) .

Short communication

Show author(s) (2023). A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC. Journal of Clinical Oncology.

Doctoral dissertation

Show author(s) (2018). Regulatory patterns in prostate cell differentiation – investigation of transcription factors AR, GATA2 and NKX3-1.

Academic chapter/article/Conference paper

Show author(s) (2017). Models of Tumor Progression in Prostate Cancer. 16 pages.

Poster

Show author(s) (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC).
Show author(s) (2023). Regulation of Indoleamine dioxygenase 1 in human dendritic cells.
Show author(s) (2023). Potential of propionyl cinobufagin for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and neuroendocrine prostate cancer (NEPC).
Show author(s) (2023). IDO-1 regulation in human dendritic cells.

Show author(s) (2022). Robust production of potent dendritic cells for cancer immunotherapy.
Show author(s) (2022). Robust and potent dendritic cells for cancer immunotherapy.
Show author(s) (2022). Novel STAT3 inhibitors targeting the STAT3 dimerization.
Show author(s) (2022). Novel STAT3 inhibitors targeting the STAT3 dimerization.
Show author(s) (2022). FLT3L and GM-CSF improve conventional dendritic cell viability and function.

Show author(s) (2020). Novel STAT3 inhibitors targeting STAT3 dimerization by binding to STAT3 SH2 domain.

Chapter

Show author(s) (2022). Models of Tumor Progression in Prostate Cancer. 453-466. In:
- Show author(s) (2022). Biomarkers of the Tumor Microenvironment. Springer.